Stefan O. Ochiana, Ph.D.

Student Associate

+1 202 408 4316 +1 202 408 4316
stefan.ochiana@finnegan.com stefan.ochiana@finnegan.com

901 New York Avenue, NW
Washington, DC 20001-4413

vCard

Show Stefan's work in

Stefan Ochiana, Ph.D., focuses his practice on patent prosecution, opinion and counseling, patent mining and mapping, and patent litigation in the chemical and pharmaceutical arts. His experience includes assisting with Abbreviated New Drug Application (ANDA) litigations under the Hatch-Waxman Act and inter partes review (IPR) proceedings at the U.S. Patent and Trademark Office (USPTO).

Prior to joining Finnegan, Stefan worked as a post-doctoral research scholar at Memorial Sloan Kettering Cancer Center. His work included several projects aimed at the discovery and development of heat shock protein 90 (Hsp90), Hsp70, glucose-regulated protein 94 inhibitors, and the design and synthesis of chemical probes for the biological evaluation of these targets.

Stefan's graduate dissertation research focused on the design, synthesis, and evaluation of human aurora kinase and phosphodiesterase inhibitors for anti-trypanosomal drug discovery via target repurposing. Stefan has a wide range of technical experience, including the areas of organic and medicinal chemistry, computational chemistry, drug delivery, preclinical drug development, and chemical biology. He has authored or co-authored fifteen journal papers and a book chapter, presented his research at thirteen national and local conferences, and is a co-inventor on three patent applications related to his postdoctoral work.

Et Cetera

American Cancer Society Postdoctoral Fellowship, 2014.
Dissertation Completion Fellowship, Office of the Provost, Fall 2012.
The Outstanding Teaching Assistant Award, Northeastern University, Department of Chemistry and Chemical Biology, 2009.
Coauthor. "Ligand Deconstruction: Why Some Fragment Binding Positions Are Conserved and Others Are Not," Proceedings of the National Academy of Sciences, USA, 2015.
Coauthor. "Structure-Activity Relationship in a Purine-Scaffold Compound Series with Selectivity for the Endoplasmic Reticulum Hsp90 Paralog Grp94," Journal of Medicinal Chemistry, 2015.
Coauthor. "Selective Targeting of the Stress Chaperome as a Therapeutic Strategy," Trends in Pharmacological Sciences, 2014.
Coauthor. "Heat Shock Protein 90 Inhibitors in the Treatment of Cancer: Current Status and Future Directions," Expert Opinion on Investigational Drugs, 2014.
Coauthor. "Designing Drugs Against Hsp90 for Cancer Therapy," The Molecular Chaperones Interaction Networks in Protein Folding and Degradation, Sept. 2, 2014.
Coauthor. "The Human Aurora Kinase Inhibitor Danusertib Is a Lead Compound for Anti-Trypanosomal Drug Discovery Via Target Repurposing," European Journal of Medicinal Chemistry, 2013.

News

Announcement

Finnegan Announces 2019 Mentors of the Year Finnegan Announces 2019 Mentors of the Year

December 30, 2019

Professional Activities

American Bar Association
American Chemical Society

Admissions and Education

Admissions

U.S. Patent and Trademark Office

Education

George Washington University Law School: J.D., expected 2021

Northeastern University: Ph.D., Organic Chemistry, 2013

Saint Vincent College: B.S., Biochemistry, 2008

Languages

Romanian

Stefan's Practices

Patent Litigation: Branded Hatch-Waxman (ANDA)
Patent Office Examinations: Prosecution
Patent Portfolio Management, Monetization, and Transactions: Due Diligence; Opinions and Counseling; Patent Mining and Mapping
Post-Grant Proceedings: IPR, PGR, and CBM

Stefan's Industries

Energy: Chemical
Life Sciences: Biotechnology; Pharmaceutical